| Company Name: |
|
| Tel: |
13366115949 |
| Email: |
|
| Products Intro: |
Cas:
ProductName:921230 Trimethoprim-sulfamethoxazole (1:19) SXT 0.002-32
|
| Company Name: |
Jiangsu Rongshuo Pharmaceutical Co., Ltd
|
| Tel: |
0000-15105138935 15105138935 |
| Email: |
2622104407@qq.com |
| Products Intro: |
Cas:723-46-6
ProductName:Sulfamethoxazole
Purity: 99% | Package: 1kg/RMB 150
|
| Company Name: |
Hu' nan Yunbang Pharmaceutical Co., Ltd.
|
| Tel: |
85561037 15386497078 |
| Email: |
yunbang@yunbangapi.com |
| Products Intro: |
Cas:723-46-6
ProductName:Sulfamethoxazole
Sulfamethoxazole
Purity: 98% | Package: 现货;按需包装
|
- Sulfamethoxazole
-
- $10.70
-
2026-05-28
- CAS:723-46-6
- Min. Order: 10kg
- Purity: 99%
- Supply Ability: 10000kg
- Sulfamethoxazole
-
-
2023-02-24
- CAS:723-46-6
- Min. Order: 100mg
- Purity: ≥98%(HPLC)
- Supply Ability: 100 g
|
| | Sulfamethoxazole/Trimethoprim Basic information |
| Product Name: | Sulfamethoxazole/Trimethoprim | | Synonyms: | SMZ/TMP;Sulfamethoxazole/Trimethoprim;Trimethoprim-Sulfamethoxazole Combination;TRIMETHOPRIM/SULPHAMETHOXAZOLE;Chemitrim;Septrim;Cotrimoxazole, Ready Made Solution;TMP-SMX | | CAS: | 8064-90-2 | | MF: | C24H29N7O6S | | MW: | 543.6 | | EINECS: | | | Product Categories: | | | Mol File: | 8064-90-2.mol |  |
| | Sulfamethoxazole/Trimethoprim Chemical Properties |
| Hazard Codes | Xi | | Risk Statements | 36/37/38-43 | | Safety Statements | 26-36/37 | | WGK Germany | 3 | | RTECS | UV8240000 | | Storage Class | 12 - Non Combustible Liquids | | Hazard Classifications | Aquatic Chronic 3
Repr. 2 | | Hazardous Substances Data | 8064-90-2(Hazardous Substances Data) | | Toxicity | LD50 orally in mice: 5513 mg/kg (Yamamoto) |
| | Sulfamethoxazole/Trimethoprim Usage And Synthesis |
| Uses | Cotrimoxazole is an antibiotic. Pseudomonas aeruginosa has a drug resistant rate of 66% in the years 2010-2013. | | World Health Organization (WHO) | The combination of sulfamethoxazole and trimethoprim (5:1) was
introduced in 1971 for the treatment of a wide variety of bacterial infections. Its use
has been associated with severe sensitivity reactions, many of which have been
attributed to the sulphonamide component. Elderly people seem to be more
vulnerable. The World Health Organization has no information further to the above
concerning restrictive action taken on this combination. | | Biological Activity | Cotrimoxazole, a combination of trimethoprim and sulfamethoxazole, interferes with the cellular metabolism of folic acid in the bacterial cell by blocking the biosynthesis of nucleotides. Trimethoprim binds to dihydrofolate reductase (DHFR) which inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF), resulting in an antimicrobial effect. Sulfamethoxazole interferes with the synthesis of nucleic acids in sensitive microorganisms by blocking the conversion of p-aminobenzoic acid to the coenzyme dihydrofolic acid. The net effect of these actions is to inhibit thymidine synthesis which prevents bacterial DNA synthesis. | | Side effects | Trimethoprim/sulfamethoxazole on a daily basis has a rapid onset of action
but has rare associated side effects of bone marrow suppression and toxic
epidermal necrolysis (TEN).
Nausea, vomiting, and anorexia are generally dose related.
Hypersensitivity reactions (including Stevens-Johnson syndrome and hematologic
reactions) occur in <5% of patients. | | Dosage forms | One to two tablets a day. Trimethoprim is dosed at 200 mg/24 hours
given either q.d. or b.i.d. |
| | Sulfamethoxazole/Trimethoprim Preparation Products And Raw materials |
|